Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Craig L. Leonardi, Alexa B. Kimball, Kim Papp, +6

The Lancet

76-Week ResultsImmunologyClinical TrialsClinical DermatologyPhoenix 1 +5

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Kim Papp, Richard G. Langley, Mark Lebwohl, +9

The Lancet

ImmunologyClinical TrialsClinical DermatologyPlacebo-controlled TrialDermatology +5

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

Kristian Reich, Frank O. Nestlé, Kim Papp, +6

The Lancet

Infliximab InductionSystemic TreatmentPhase IiiClinical TrialsPsoriatic Arthritis +5

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

C.E.M. Griffiths, Bruce Strober, Peter van de Kerkhof, +10

New England Journal of Medicine

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Andrew Blauvelt, Kim Papp, C.E.M. Griffiths, +5

Journal of the American Academy of Dermatology

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

Iain B. McInnes, Arthur Kavanaugh, Alice B. Gottlieb, +8

The Lancet

Rheumatoid DisorderRheumatologyAutoimmune DiseaseMedicineRheumatic Diseases +9

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

Kristian Reich, April W. Armstrong, Peter Foley, +6

Journal of the American Academy of Dermatology

Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial

Christopher T. Ritchlin, Proton Rahman, Arthur Kavanaugh, +8

Annals of the Rheumatic Diseases

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

Alice B. Gottlieb, Alan Menter, Alan M. Mendelsohn, +6

The Lancet

RheumatologyAutoimmune DiseaseCrossover TrialMedicineRheumatic Diseases +8

Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trial

Alice B. Gottlieb, Robert J. Evans, Shu Li, +6

Journal of the American Academy of Dermatology

RheumatologyAutoimmune DiseaseMedicineSystemic TreatmentImmunology +9